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Abstract 
Introduction 
Intravenous antibiotic prophylaxis is not recommended in acute pancreatitis.  According to current 
international guidelines antibiotics together with further intervention should be considered in the setting 
of infected necrosis. Appropriate antibiotic therapy particularly avoiding over-prescription is important.  
This study examines antibiotic use in acute pancreatitis in a tertiary centre using the current IAP/APA 
guidelines for reference. 
Methods 
Data were collected on a consecutive series of patients admitted with acute pancreatitis over a 12 
month period.  Data were dichotomized by patients admitted directly to the centre and tertiary transfers.  
Information was collected on clinical course with specific reference to antibiotic use, episode severity, 
intervention and outcome. 
Results 
111 consecutive episodes of acute pancreatitis constitute the reported population.  31 (28%) were 
tertiary transfers. Overall 65 (58.5%) patients received antibiotics.  Significantly more tertiary transfer 
patients received antibiotics. Mean person-days of antibiotic use was 23.9 (sd 29.7) days in the overall 
study group but there was significantly more use in the tertiary transfer group as compared to patients 
having their index admission to the centre (40.9 sd 37.1 vs 10.2 sd 8.9; P<0.005). Thirty four (44%) of 
patients with clinically mild acute pancreatitis received antibiotics  
Conclusions 
There is substantial use of antibiotics in acute pancreatitis, in particular in patients with severe disease. 
Over-use is seen in mild acute pancreatitis. Better consideration must be given to identification of 
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prophylaxis or therapy as indication.  In relation to repeated courses of antibiotics in severe disease 
there must be clear indications for use.   
[abstract word count: 245 ]. 
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Introduction 
Infection of pancreatic necrosis is the most frequent cause of late mortality in severe acute pancreatitis 
[1-3].  Antibiotic prophylaxis to reduce infective complications in acute pancreatitis was evaluated in a 
series of randomized trials [4-12]. However meta-analyses of these trials do not support antibiotic 
prophylaxis in acute pancreatitis [13-15].  Summarising this evidence, the International Association of 
Pancreatology/American Pancreatic Association (IAP/APA) produced evidence-based guidelines in 
2013 for the management of acute pancreatitis. These  state that intravenous antibiotic prophylaxis is 
not recommended for the prevention of infective complications in acute pancreatitis. The guidelines 
support antibiotic use in “case of suspected infection of necrotizing pancreatitis” together with 
consideration for further intervention [16]. 
Given the dearth of specific, effective interventions in acute pancreatitis, optimal use of antibiotics is 
important.  Under-use may lead to inadequate treatment of infection whereas over-use encourages 
emergence of resistant bacterial flora and leads to a reduction in available treatments if and when 
infection does occur.  In clinical practice it is likely that the reasons underlying antibiotic use and mis-
use in acute pancreatitis are complex and multi-factorial.  Arguably, the most frequent confounding 
factor is that making a distinction between infection and the systemic inflammatory response of 
pancreatitis at the bedside can be difficult.  Clinical signs such as fever and tachycardia may be similar 
and both scenarios are associated with an elevated leukocyte count and C-reactive protein.  Further, 
infection and systemic inflammation can co-exist.  Poor compliance with guidelines for antibiotic use in 
acute pancreatitis is a genuine and important clinical problem seen worldwide [17].  In order to better 
understand antibiotic use in the contemporary management of acute pancreatitis this study takes the 
form of an overview of management in a tertiary referral specialist hepato-pancreato-biliary (HPB) 
centre.  The study examined antibiotic use in patients admitted directly to the centre and also in tertiary 
referral patients initially admitted to other hospitals and transferred during the course of their episode of 
acute pancreatitis.  The current IAP/APA guidelines were used as a reference standard.  
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Methods 
Design and setting 
This is a single-centre clinical cohort study based in the regional specialist HPB service of the 
Manchester Royal Infirmary (MRI) which serves a 3.2 million predominantly urban conurbation of the 
Greater Manchester and Cheshire Cancer Network. 
Study period 
The inclusion period is the 12 months from 1st October 2014 to 1st October 2015.  
Definitions of acute pancreatitis 
The diagnosis of acute pancreatitis was confirmed by the presence of (typically) severe epigastric pain 
accompanied with ≥ 3-fold elevation in serum amylase or by characteristic findings on contrast-
enhanced CT scan. Clinical severity of acute pancreatitis (mild, moderate, severe) was assessed 
according to the revised Atlanta classification (2012), based on the presence of transient organ failure 
and local or systemic complications [18].  The diagnosis of infected pancreatic necrosis was based on 
positive culture of drained peripancreatic fluid or gas containing collection on CT.   
Data collection 
Data were collected prospectively from 1st January 2015 (retrospectively for the preceding three months 
to complete the 12 month study period) by accessing patient notes and using a bespoke case-report 
form.  All data were collected from time of admission to the tertiary care centre including calculation of 
Acute Physiology and Chronic Health Evaluation (APACHE II) and Marshall Organ Dysfunction scores 
(MODS).  All patients ≥18 years old admitted with acute pancreatitis were included in the study. Data 
were collected on demographic profile, days of in-patient stay and setting (in-patient ward, High 
Dependency unit with non-invasive ventilation or critical care with ventilatory support) whether the index 
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admission was to this hospital or whether the patient was a tertiary transfer. Re-admitted patients were 
remained in their originally allocated category (for example an index admission patient who was re-
admitted, remained an index admission). Data were collected on aetiology [biliary, alcohol, endoscopic 
retrograde cholangiopancreatography(ERCP)-induced, drug-induced, traumatic or idiopathic], 
admission amylase and C-reactive protein.   
Antibiotic use 
Use of antibiotics was recorded together with number of days of treatment (defined as person-days of 
antibiotic use).  During the period of this study there was published guidance for the tertiary centre 
relating to antibiotic use based on and complying with the IAP/APA guidelines [16].  To further explore 
the use of antibiotics in this disease, use was categorised as either for acute pancreatitis (for example 
severe disease or presence of infected necrosis) or for a secondary condition during in-patient stay 
such as upper respiratory tract infection.  
Use of computed tomography (CT) 
Use of CT scan was recorded and Balthazar CT severity score calculated for the purposes of the study 
[19].  For tertiary transfer patients, the information relating to CT refer to scans undertaken in this 
centre. 
Radiologic, endoscopic and surgical interventions 
Fine needle aspiration of pancreatic necrosis was not routinely employed in this unit during the period 
of this study.  A record was made of other radiologic intervention such as percutaneous catheter 
drainage and also angiographic radiological intervention such as mesenteric angiographic embolization 
undertaken during index admission.  Endoscopic interventions undertaken during the index admission 
were recorded.  Similarly, surgical interventions were recorded. For the purposes of this study, surgical 
necrosectomy refers to minimally invasive necrosectomy. 
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Analysis plan 
Management of patients admitted for acute pancreatitis was summarised descriptively for study 
variables, including demographics, disease and management variables, in particular number of days of 
antibiotic treatment and type of antibiotic used.  Use of antibiotics was assessed for compliance with 
the IAP/APA guideline recommendations and contrasted for index and tertiary transferred patients. The 
influence of level of antibiotic use and adherence to guidelines upon confirmed infection rates, GI 
complications and length of stay was explored using appropriate general linear models adjusted for 
recorded patient, disease and management factors and covariates. Thus a p-value of < 0.05 was 
considered to indicate statistical significance for findings meriting further investigation without 
adjustment for multiple comparisons.  Bootstrapped estimation was used for continuous variables, 
analysis of proportions used Fisher’s exact test.  Analysis was conducted using SPSS v21 (IBM Corp; 
IBM SPSS Statistics for Windows, Version 21.0, Armonk, NY, USA). 
Ethics. 
The study was categorised as an audit by the Central Manchester Hospitals Foundation Trust Research 
and Development office and was registered with the hospital’s audit department (audit number 6513). 
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Results 
Demographic profiles 
111 consecutive episodes of acute pancreatitis constitute the reported population.  Of these, 31 (28%) 
were initially admitted to other hospitals across the region and subsequently transferred to this centre 
for tertiary care.  The demographic characteristics are seen in Table 1.  Ten tertiary referral patients 
were transferred with a MODS score of 1 or 2.  Gallstones were the most frequent cause of acute 
pancreatitis with alcohol being the second most common cause.  
Disease severity 
There were significantly more episodes of radiologically and clinically severe acute pancreatitis in the 
tertiary transfer group.  Physiological derangement was worse in transferred patients with haemoglobin 
and albumin being significantly lower at time of transfer (table 2).  
Index admissions compared to tertiary transfer 
There was no significant difference in age between those patients admitted directly to the MRI and 
those admitted as tertiary transfers (55.6 SD 20 vs 54.3 SD 14.7; p = 0.712). Thirty nine (49.4%) of 
patients having their index admission to the MRI had an MODS score of 0 compared to 18 (64.3%) of 
tertiary transfers by the time of their arrival (p=0.062). Pancreatitis severity was worse in transfer 
patients. The index admission MOD scores have a much longer tail of severity than the tertiary 
variables. 
Diagnostic and interventional radiology 
CT severity index was significantly worse in patients who were tertiary transfers (7.3 ± 2.8 vs 3.1 ± 2.5; 
P <0.001).  19 (61.3%) of patients who were tertiary transfers underwent percutaneous catheter 
drainage compared to 3 (3.7%) who had their index admission to the tertiary centre. 
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Endoscopic and surgical interventions 
Eighteen patients (16.2%) underwent ERCP ± stent.  All patients undergoing necrosectomy in this 
series were admitted with severe acute pancreatitis.   
Antibiotic use 
Overall 65 (58.5%) patients received antibiotics.  Significantly more tertiary transfer patients received 
antibiotics. Mean person-days of antibiotic use was 23.9 (sd 29.7) days in the overall study group but 
there were significantly more person days of antibiotic use in the tertiary transfer group as compared to 
patients having their index admission to the centre (40.9 sd 37.1 vs 10.2 sd 8.9; P<0.005). 
Assessed by episode severity (table 3), 34 (44%) of patients with clinically mild acute pancreatitis 
received antibiotics although in 10 (13%) of these patients, the indication was for infective 
complications occurring during the inpatient admission with acute pancreatitis (table 3).  In contrast, 17 
(100%) patients with severe acute pancreatitis received antibiotics. There was a broad range of 
antibiotics used (table 4) with the combination of amoxicillin and clavulanic acid being the most 
frequently prescribed (30 patients [27%]).  Fourteen patients (12.6%) had two antibiotic regimens, 12 
(10.8%) receiving 3 distinct courses of antibiotics and 5 (4.5%) patients receiving four courses. 
Antibiotic guideline compliance 
Twenty four patients (30.7%) of patients with mild disease received antibiotics which would not be 
recommended in the IAP/APA guideline.  All patients with severe disease received antibiotics and 14 of 
17 (82%) of patients with moderate disease received antibiotics. 
Outcome 
Overall median episode-related in-patient stay was 11 (range 1 – 133) days.  Median in-patient stay in 
patients with severe disease was 31 (8-89) days with 14 (0-46) of this being spent in critical care.  
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Patients with mild disease spent a median of 9 (1-52) days as in-patients with a median of 0 (0-6) in 
critical care. Overall episode-related death occurred in 4 patients giving a mortality rate of 3.6% with all 
these deaths occurring in patients with severe acute pancreatitis. 
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Discussion 
This study is a selective audit of the management of patients with acute pancreatitis in a tertiary 
specialist HPB centre with special emphasis on antibiotic use.  An important potential methodological 
limitation is that it can be difficult to ascertain why any given individual was prescribed antibiotics in a 
given setting and this should be borne in mind in particular in relation to guideline compliance in this 
disease of considerable complexity. 
In relation to the findings of this study it is apparent that patients who are transferred for tertiary care 
comprise a discrete subgroup of patients with acute pancreatitis. As expected, they represent cases of 
greater severity, and correspondingly the antibiotic use is higher and hospital stay is more prolonged.   
Sixty five (58.5%) received antibiotics.  Twenty four (30.7%) of patients with mild acute pancreatitis 
received antibiotics in the absence of any recorded intercurrent infection suggesting that this use was 
not in compliance with IAP/APA guidelines.  Assessment of compliance in patients with severe acute 
pancreatitis is more problematic: although all patients with severe disease received antibiotics it is 
difficult to be certain with precision whether use was for documented infection.   
When dichotomized by index or tertiary admission there was significantly more antibiotic use in patients 
who were tertiary transfers compared to those having their index admission to the centre (40.9 sd 37.1 
person days vs 10.2 sd 8.9 person days; P<0.005).  It should also be noted that these data do not 
include antibiotic use in tertiary transfer patients prior their transfer.  In keeping with the prolonged in-
patient stay seen in patients with severe acute pancreatitis, the majority of patients had more than one 
regimen of antibiotics with 10.8% receiving three courses.     
The study shows that there is substantial use of antibiotics during the clinical course of acute 
pancreatitis.  First, there seems to be overuse of antibiotics in patients with mild acute pancreatitis.   In 
this setting, unless there is an indication for use of antibiotics for treatment of intercurrent infection there 
is no benefit from antibiotic use and a risk of harm.  With respect to patients with severe disease, when 
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considering the multiple antibiotic regimens used there is a need for continued vigilance and precision 
in use of antibiotics.  Multiple courses of broad-spectrum antibiotics create a high risk of encouraging 
emergence of resistant flora in a subset of patients with severe disease and physiological impairment. 
In summary, this study examines a very common issue in everyday clinical management: that of 
antibiotic use in acute pancreatitis.  In the context of the healthcare system wherein the study was set 
there is evidence of over-use of antibiotics in patients with mild acute pancreatitis.  Although antibiotics 
are a necessary component of treatment in patients with severe acute pancreatitis, better consideration 
must be given to identification of prophylaxis or therapy as indication of use and in relation to repeated 
courses of broad-spectrum antibiotics there must be a clear indication for use.  This audit highlights 
areas of potential inappropriate use.  The study shows the need for better adherence to guidelines.  Re-
audit after better dissemination of the information contained in the IAP/APA guidelines is planned.  
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Table 1: Patient characteristics and Treatment (categorical variables) 
  Total  Index admissions 
to MRI 
 Tertiary referrals.  
  Count (%)  Count (%)  Count  (%) p (2-s)+ 
Gender 
 Male 62 (55.9%)  41 (51.3%)  21 (67.7%) 0.139 
 Female 49 (44.1%)  39 (48.8%)  10 (32.3%)  
Admission MODS score 
 0 57 (49.4%)  39 (49.4%)  18 (64.3%) 0.062 
 1 29 (27.8%)  22 (27.8%)  7 (25.0%)  
 2 11 (10.1%)  8 (10.1%)  3 (10.7%)  
 3 4 (5.1%)  4 (5.1%)  0 (0.0%)  
 4 3 (3.8%)  3 (3.8%)  0 (0.0%)  
 5 2 (2.5%)  2 (2.5%)  0 (0.0%)  
 6 1 (1.3%)  1 (1.3%)  0 (0.0%)  
Aetiology 
 Not recorded 5 (5.0%)  4 (5.0%)  1 (3.2%) 0.962 
 Biliary 53 (48.8%)  39 (48.8%)  14 (45.2%)  
 Alcohol 27 (22.5%)  18 (22.5%)  9 (29.0%)  
 Drug-related 6 (5.0%)  4 (5.0%)  2 (6.5%)  
 ERCP-induced 6 (5.0%)  4 (5.0%)  2 (6.5%)  
 Hypertriglyceridaemia 3 (3.8%)  3 (3.8%)  0 (0.0%)  
 Idiopathic 11 (10.0%)  8 (10.0%)  3 (9.7%) 
 
 
 
Pancreatitis CT severity 
 Mild 19 (29.7%)  18 (50.0%)  1 (3.6%) <0.001 
 Moderate 16 (14.4%)   4 (5 %)  12 (38.7%)  
 Severe 17 (15.3%)  6 (7.5%)  11 (35.5%)  
Pancreatitis clinical severity 
 Mild 78 (70.3%)  70 (87.5%)  8 (25.8%) <0.001 
 Moderate 17 (15.3%)  5 (6.3%)  12 (38.7%)  
 Severe 16 (14.4%)  5 (6.3%)  11 (35.5%)  
Interventions 
Radiology 
 None 86 (77.5%)  75 (93.8%)  11 (35.5%) 0.485 
 Percutaneous drain 22    (20%)  3 (3.7%)  19 (61.3%)  
 Mesenteric  
Embolisation 
5 (4.5%)  3 (3.8%)  2 (6.4%)  
           
Surgery 
 None 108 (97.3%)  80 (100.0%)  28 (90.3%) 0.020 
 Necrosectomy 3 (2.7%)  0 (0.0%)  3 (9.7%)  
Endoscopy 
 None 90 (81.1%)  62 (77.5%)  28 (90.3%) 0.206 
 ECRP ± stent 18 (16.2%)  16 (20.0%)  2 (6.5%)  
 Endoscopic 
necrosectomy 
3 (2.7%)  2 (2.5%)  1 (3.2%)  
Antibiotic use 
 No 46 (41.4%)  44 (55%)  2 (6.4%) <0.001 
 Yes 65 (58.5%)  36 (45%)  29 (93.5%)  
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Table 2: Patients’ characteristics and Treatment (continuous variables) 
Variables Total (N=111)  MRI (n=80)  Referral (n=31)  Referral-MRI 
 Mean SD  Mean SD  Mean SD  Difference 95%CI+ p(2-s)+ 
Age 55.3 18.6  55.6 20.0  54.3 14.7  -1.3 (-8. to 5.4) 0.712 
Scoring and blood tests  
on admission 
APACHE II 
 
 
6.4 
 
 
3.3 
  
 
6.1 
 
 
3.5 
  
 
7.1 
 
 
2.7 
  
 
1.1 
 
 
(-0.2 to 2.3) 
 
 
0.112 
Hb  124.1 25.8  134.9 20.5  96.0 14.5  -38.9 (-45.5 to -32.2) <0.001 
WBC  13.6 7.0  12.7 4.8  16.1 10.4  3.5 (-0.1 to 7.5) 0.101 
Amylase  853.2 929.8  987.5 961.1  190.7 226.2  -796.8 (-1041.4 to -556) <0.001 
Urea  6.0 3.9  5.8 3.4  6.5 5.0  0.8 (-1.1 to 2.8) 0.445 
Creatinine  96.8 88.3  103.0 99.6  80.5 45.5  -22.5 (-50.5 to 3.) 0.114 
Bilirubin  25.0 39.5  29.4 45.2  13.8 14.0  -15.6 (-27.3 to -5.3) 0.019 
Alkaline phosphatase  159.1 147.7  134.6 91.7  221.5 227.5  86.8 (11.2 to 175.2) 0.057 
Albumin  29.8 9.7  34.0 7.4  19.0 5.9  -15.0 (-17.6 to -12.4) <0.001 
CRP 
Severity  
107.2 126.9  71.9 109.0  196.1 126.7  124.3 (73.8 to 175.) <0.001 
Delay to first CT in MRI (days) 4.6 4.7  4.1 4.3  5.3 5.1  1.2 (-1. to 3.6) 0.300 
CT severity index (Balthazar) 
Antibiotics 
4.9 3.4  3.1 2.5  7.3 2.8  4.3 (2.9 to 5.5) <0.001 
Person-days of antibiotics* 
Hospital stay 
23.9 29.7  10.2 8.9  40.9 37.1  30.7 (17.1 to 46.2) 0.005 
HDU stay (days)** 1.1 5.1  0.1 0.8  3.8 9.4  3.6 (0.6 to 7.6) 0.116 
ITU stay (days)*** 1.2 5.4  0.1 0.4  4.2 10.1  4.1 (0.9 to 8.3) 0.081 
Total stay (days) 18.4 23.0  12.2 10.2  35.9 36.5  23.7 (11.1 to 38.3) 0.015 
+ bootstrapped estimation 
* In patients receiving antibiotics 
**HDU= High Dependency Unit with non-invasive ventilatory support available. 
***ITU=Intensive Care Unit with invasive (endotracheal) ventilatory support and renal replacement therapy available. 
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Table 3. Antibiotic use and outcome in mild, moderate and severe acute pancreatitis 
 Pancreatitis clinical severity 
  Mild Moderate Severe Total 
Number of Patients (n) 78 (70%) 16 (14%) 17 (15%) 111  
Antibiotic use 
     Indication not related to   
pancreatitis: 
          Cholecystitis 
          Cholangitis 
          Chest infection 
          Urinary tract infection 
          MRSA/VRE/CPE*  
          Clostridium difficile infection 
          Post-ERCP prophylaxis 
     
34 (44%) 
10 (13%) 
 
1 
1 
0 
3 
2 
1 
2 
 
13 (81%) 
2 (15%) 
 
0 
0 
1 
0 
0 
1 
0 
 
17 (100%) 
3 (18%) 
 
0 
0 
1 
0 
2 
0 
0 
 
64 (57.6%) 
15 (14%) 
 
1 
1 
2 
3 
4 
2 
2 
 
Hospital stay (days - median/range) 
    Total 
    High dependency /Intensive care unit 
 
9 (1-52) 
0 (0-6) 
 
23 (2-133) 
0 (0-24) 
 
31 (8-89) 
14 (0-46) 
 
11 (1-133) 
0 (0-46) 
Mortality 0 0  4 (23.5%) 4 (3.6%) 
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Table 4: Frequency of use of antibiotics 
 Count (%) 
Use of antibiotic regimens   
Amoxicillin + Clavulanic acid 30 (27.0%) 
Ciprofloxacin 11 (9.9%) 
Clarythromycin 1 (0.9%) 
Colistin 2 (1.8%) 
Fidaxomicin 1 (0.9%) 
Flucloxacillin  1 (0.9%) 
Fluconazole 4 (3.6%) 
Gentamycin 6 (5.4%) 
Meropenem 21 (18.9%) 
Metronidazole 22 (19.8%) 
Moxifloxacin 1 (0.9%) 
Penicillin V 1 (0.9%) 
Piperacillin + Tazobactam 27 (24.3%) 
Vancomycin 2 (1.8%) 
Teicoplanin 3 (2.7%) 
Tigecycline 9 (8.1%) 
Number of antibiotic regimens per patient 
0 53 (47.7%) 
1 20 (18.0%) 
2 14 (12.6%) 
3 12 (10.8%) 
4 5 (4.5%) 
5 5 (4.5%) 
6 2 (1.8%) 
7 1 (0.9%) 
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Table legends  
 Legend table 1 
+ Unordered categorical data MRI vs. Referral: Fisher's exact test; Ordered categorical data MRI 
vs. Referral: exact test for linear association.  Admission MODS score for tertiary referral patients is 
calculated from point of admission to the tertiary care specialist unit at MRI and not from time of 
admission (admission MODS scores for these patients not available). 
Legend Table 2 
Hb = Haemoglobin (g/L); WBC = White Blood Cell Count ( x 109/L); CRP = C-reactive protein 
(international units). 
Legend table 3 
* MRSA: Methicillin Resistant Staphylococcus Aureus, VRE: Vancomycin Resistant Enterococci,  
CPE: Carbapenemase-producing Enterobacteriaceae  
 
 
 
 
 
 
 
 
